Deutsche Bank Ag\ Infla Rx N.V. Transaction History

Deutsche Bank Ag\

$245 Billion
Q1 2025

A detailed history of Deutsche Bank Ag\ transactions in Infla Rx N.V. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 200 shares of IFRX stock, worth $162. This represents 0.0% of its overall portfolio holdings.

Number of Shares

200

Holding current value

$162

% of portfolio

0.0%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 09, 2025	BUY	$1.02 - $2.62 $204 - $524	200 New	200 $0
Q3 2019 Nov 14, 2019	SELL	$2.47 - $3.51 $2,470 - $3,510	-1,000 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$3.06 - $51.61 $261,070 - $4.4 Million	-85,317 Reduced 98.84%	1,000 $3,000
Q1 2019 May 15, 2019	BUY	$31.16 - $48.62 $1.6 Million - $2.5 Million	51,317 Added 146.62%	86,317 $3.26 Million
Q4 2018 Feb 14, 2019	SELL	$23.33 - $36.37 $142,219 - $221,711	-6,096 Reduced 14.83%	35,000 $1.27 Million
Q3 2018 Nov 14, 2018	BUY	$29.34 - $35.0 $170,054 - $202,860	5,796 Added 16.42%	41,096 $1.41 Million
Q2 2018 Aug 14, 2018	BUY	$27.33 - $41.46 $8,199 - $12,438	300 Added 0.86%	35,300 $1.14 Million
Q4 2017 Feb 14, 2018	BUY	$14.55 - $23.99 $509,250 - $839,650	35,000	35,000 $733,000

Others Institutions Holding IFRX

# of Institutions

Shares Held

18.2M

Call Options Held

33.6K

Put Options Held

2.2K

Suvretta Capital Management, LLC New York, NY

6.48M
Shares

$5.25 Million
0.29% of portfolio
683 Capital Management, LLC New York, NY

2.63M
Shares

$2.13 Million
0.22% of portfolio
Eversept Partners, LP New York, NY

1.68M
Shares

$1.36 Million
0.19% of portfolio
Morgan Stanley New York, NY

1.26M
Shares

$1.02 Million
0.0% of portfolio
Silverarc Capital Management, LLC

1.16M
Shares

$940,869
0.29% of portfolio

View Full List

About InflaRx N.V.

Ticker IFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,203,800
Market Cap $35.8M
Description
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...

More about IFRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account